MoneyWorks4Me

Glenmark Pharmaceuticals informs about media release

21 Mar 2026 Evaluate
Glenmark Pharmaceuticals has informed that the company research-led, global pharmaceutical company, today announced the launch of GLIPIQ® (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients. The company has attached media release.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharma. Share Price

2440.00 45.00 (1.88%)
26-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1901.00
Dr. Reddys Labs. 1186.40
Cipla 1408.40
Lupin 2191.20
Zydus Lifesciences 1147.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: